The hormones you need after a hysterectomy depend on one key factor: whether your ovaries were removed. If they were, you’ve entered surgical menopause and will likely need hormone replacement. If your ovaries are intact, they continue producing hormones on their own, and you may not need any replacement at all. For most women without a uterus, the primary hormone prescribed is estrogen, taken alone without a progestogen.
Why Estrogen Alone Is the Standard
When both the uterus and ovaries are removed, your body loses its main source of estrogen virtually overnight. This triggers immediate menopause, often with more intense symptoms than natural menopause because the hormonal drop is sudden rather than gradual. Hot flashes, night sweats, sleep disruption, vaginal dryness, and mood changes can begin within days of surgery.
Estrogen-only therapy is the go-to treatment in this situation. In women who still have a uterus, estrogen must be paired with a progestogen to prevent the uterine lining from thickening abnormally, which raises the risk of endometrial cancer. Once the uterus is gone, that risk disappears, so the progestogen becomes unnecessary. This makes the regimen simpler and avoids potential side effects from the second hormone.
The North American Menopause Society considers hormone therapy the most effective treatment for hot flashes and the cluster of vaginal and urinary symptoms that follow menopause. It also prevents bone loss and fractures.
How You Take It Matters
Estrogen comes in several forms: skin patches, gels, sprays, and oral tablets. The delivery method isn’t just a matter of convenience. It affects your safety profile, particularly your risk of blood clots.
A systematic review comparing transdermal (patch or gel) and oral estrogen found consistent evidence that oral estrogen raises the risk of blood clots, while transdermal estrogen does not. One large study found oral estrogen carried a relative risk of 3.5 for clots compared to 0.9 for transdermal, meaning patches essentially carried no increased risk at all. This difference exists because swallowed estrogen passes through the liver first, triggering production of clotting factors. Estrogen absorbed through the skin bypasses the liver entirely.
For heart health and cholesterol, the two routes appear roughly equivalent. Most studies show no significant difference in cardiovascular outcomes or improvements to cholesterol profiles between patches and pills. So the main advantage of transdermal estrogen is its lower clot risk, which matters most for women who are overweight, smoke, have a family history of blood clots, or carry certain genetic clotting mutations.
When Testosterone Enters the Picture
Some women notice a significant drop in sex drive after their ovaries are removed, since the ovaries produce about half the body’s testosterone. If low sexual desire persists after estrogen therapy is established and other causes have been ruled out (relationship issues, medication side effects from antidepressants, stress), testosterone supplementation may help.
There are no testosterone products specifically licensed for women in most countries. Instead, doctors prescribe male testosterone gels or creams at roughly one-tenth the male dose. A typical starting dose delivers about 5 mg of testosterone per day, applied to the skin. The British Menopause Society recommends that vaginal dryness and other genital symptoms be properly treated before adding testosterone, since these alone can suppress desire and comfort during sex.
The Case for Progesterone Without a Uterus
While progesterone isn’t routinely prescribed after hysterectomy, some research suggests it offers bone benefits beyond what estrogen provides alone. In randomized trials, women taking estrogen plus a progestogen gained more bone density in the spine than those on estrogen alone. One study in New Zealand found a 65% greater increase in spinal bone density with the combination compared to estrogen by itself. Some clinicians also prescribe progesterone for its calming, sleep-promoting effects, though this remains a case-by-case decision rather than standard practice.
Starting HRT After Surgery
If your ovaries were removed during the hysterectomy, there’s generally no reason to delay starting estrogen. A study of women who had both ovaries removed for endometriosis found that those who began estrogen immediately after surgery actually had lower rates of recurring pain (7%) than those who waited more than six weeks (20%). Starting early also prevents the cascade of menopausal symptoms from taking hold in the first place.
If your ovaries were left in place, they usually keep functioning. However, some women experience earlier-than-expected menopause even with intact ovaries after hysterectomy, possibly due to changes in blood supply. If menopausal symptoms develop months or years later, hormone therapy can be started at that point.
Special Considerations for Younger Women
Women who lose their ovaries before age 45 face a longer stretch of estrogen deprivation than those who reach menopause naturally around 51. This prolonged gap raises the risk of osteoporosis, fractures, and cardiovascular disease. For these women, hormone therapy is strongly recommended at least until the average age of natural menopause, and potentially beyond.
The benefit-risk ratio of hormone therapy is most favorable for women under 60 or within 10 years of menopause onset. For women who start HRT more than 10 years after menopause or after age 60, the absolute risks of heart disease, stroke, and blood clots increase. This is why early surgical menopause calls for prompt and sustained treatment rather than a wait-and-see approach.
When Hormones Aren’t an Option
Some women cannot or choose not to take hormones. A personal history of breast cancer is the most common reason doctors advise against HRT, since some evidence suggests it may increase recurrence risk. Advanced endometrial cancer, uterine sarcoma, and certain ovarian cancers are also contraindications.
For these women, non-hormonal alternatives exist. Fezolinetant, approved by the FDA, works by blocking the brain’s temperature-regulation pathway rather than replacing hormones. In clinical trials of women experiencing at least seven hot flashes per day, the 45 mg dose reduced hot flash frequency by 57% at 12 weeks, compared to 30% with a placebo. Participants also reported better sleep and less distress from their symptoms. Paroxetine, originally developed as an antidepressant, is the only other FDA-approved non-hormonal option for hot flashes, though it’s less commonly used for this purpose.
For vaginal dryness specifically, low-dose vaginal estrogen (applied locally rather than absorbed into the whole body) or vaginal DHEA are options that deliver minimal systemic hormone exposure. These are sometimes considered even for women with hormone-sensitive cancer histories, though that decision requires careful individual evaluation.
How Long to Continue
There’s no universal stop date. The North American Menopause Society recommends periodic reevaluation of the benefits and risks, with treatment individualized through shared decision-making. Women with persistent symptoms or those who entered surgical menopause young may continue therapy for years or even decades. The key is that the reason for continuing should be documented, whether that’s ongoing hot flashes, bone protection, or quality of life, and revisited regularly with your prescriber.